News

23 | 12 | 22

Protinhi Therapeutics semi-finalist iin ZELSIF

Protinhi Therapeutics, a company located at Noviotech Campus Nijmegen,  is nominated as a semi-finalist in ZELSIF this year, and will be presenting their journey to European and Chinese medical experts and investors during the event on the 16th of December. 

The ZELSIF 2022 International Top 15 winners will receive the “ZELSIF 2022” award, which goes along with the privileged opportunity to introduce their solutions to Chinese healthcare experts, investors, and industrials through an online pitch presentation. In the next two weeks, the semi-finalist companies will compete for the top 7 final winners who will receive further awards in cash. 

Protinhi Therapeutics is an early-stage biotech company aiming to combat (emerging) viral infectious diseases with a high unmet medical need via protease inhibition. With their proprietary technology platform, they are actively developing novel antiviral drugs that inhibit proteases and block viral replication. The  aim for easy-to-administer drugs able to treat in epidemic and pandemic situations.

https://set.kuleuven.be/lhtc/News 

Posted by Karina Garcia, Kadans Science Partner.

Briskr News

All news